A Study of C105 on Cognitive Dysfunction in Persons With Multiple Sclerosis

• Status: Completed
• Trial end date: 2008-04-01

Summary

The purpose of this study is to determine the safety and efficacy of C105 in treating the cognitive deficits that can occur due to multiple sclerosis.

• Phase: Phase 2

Details

• Lead Sponsor: Cognition Pharmaceuticals, LLC